Robert Carnahan

(iStock)
October 28, 2024

VUMC discovery aids effort to stop a deadly virus in Rwanda

A close cousin of Ebola, the Marburg virus is transmitted by fruit bats and by exposure to body fluids from infected individuals. There currently are no approved treatments or vaccines for MVD, which has a roughly 50% fatality rate.

By Bill Snyder
(iStock)
September 13, 2024

VUMC joins national effort to prevent another pandemic

Developed in the wake of the COVID-19 pandemic, ReVAMPP will support a coordinating center and seven research centers, including VUMC, with a focus on nine virus groups that pose the greatest risk to human health.

By Bill Snyder
(iStock)
August 13, 2024

VUMC, DOD join forces for a hantavirus antibody “sprint”

VUMC’s antibody collaboration with the DOD goes back to 2018, when the medical center signed a five-year cooperative agreement with the U.S. Defense Advanced Research Projects Agency to develop protective treatments that can be rushed to health care providers within weeks after a viral outbreak.

By Bill Snyder
March 16, 2023

Scientists resurrect a ‘dead’ antibody to study protein

Vanderbilt was part of a multi-center team that resurrected a “dead antibody” to reveal the mysteries of cytochrome c, a versatile protein that is an essential part of the cell’s energy-generating capacity, and of life itself.

By Bill Snyder
January 12, 2023

Antibody “fingerprinting” method potential advance to slow spread of dengue

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

By Bill Snyder
Pending COVID-19 samples are prepared for testing in the Diagnostic Laboratories at VUMC.
November 3, 2022

Event to spotlight VUMC’s COVID-19 research efforts

The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.

By Bill Snyder
October 6, 2022

Vanderbilt’s Crowe receives the Building the Foundation Award from Research!America

Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization.
By Bill Snyder
August 24, 2022

COVID antibody research conducted at VUMC lands national award

A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.
By Bill Snyder
February 17, 2022

Pandemic leads to broader use of monoclonal antibodies

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
By Bill Snyder
December 23, 2021

Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness

On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.
By Bill Snyder
October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.
By Bill Snyder
August 23, 2021

‘DNA’ podcast Season 2 explores COVID, science and trust in communities

By Holly Fletcher
August 20, 2021

COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study

A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
By Bill Snyder
1 2